

Investor News

Nick Stone

Senior Vice President
Investor Relations

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2485
nick.stone@fresenius.com
www.fresenius.com

February 3, 2025

Fresenius reaches agreement to exit Vamed's international project business ahead of schedule

Fresenius entered an agreement with Worldwide Hospital Group (WWH) to fully divest Vamed's international project business (Health Tech Engineering, HTE). In May 2024, Fresenius originally announced a gradual wind-down of the HTE project business, largely to be completed by 2026, as part of Fresenius' structured exit from its Investment Company Vamed. The divestment will now accelerate the exit and enable Fresenius to further increase focus and management capacity on the ongoing progress of its core businesses Fresenius Kabi and Fresenius Helios, in line with #FutureFresenius. For the employees of Vamed's international project business, the transaction offers the perspective of the continuation of the business.

Worldwide Hospitals Group (WWH), a healthcare company based in Germany, specializes in delivering flexible modular hospital solutions—both at sea and on land. Vamed's international project business will complement and enhance WWH's core business.

Closing is expected mid of 2025 and subject to the fulfilment of certain closing conditions.

#

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2023 fiscal year, Fresenius generated €22.3 billion in annual revenue. Fresenius offers solutions to the social challenges posed by a growing and ageing population and the resulting need for affordable, high-quality healthcare. Fresenius currently counts over 175,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as the investment company Fresenius Medical Care.

Follow us on LinkedIn: www.linkedin.com/company/fresenius-investor-relations

Follow us on Twitter: www.twitter.com/fresenius_ir

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852

Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673

Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser

Chairman of the Supervisory Board: Wolfgang Kirsch